FDA Issues First Draft Guidance on Clinical Trials with Psychedelic Drugs
June 27, 2023
Businesswoman on blurred background using digital x-ray human body scan interface 3D rendering
Zephyr Group – Reg CF Offering Announcement
FOR IMMEDIATE RELEASE – March 31, 2026
Zephyr Group, Inc. (“Zephyr Group” or the “Company”) today announced that it has launched an offering of its securities pursuant to Regulation Crowdfunding (“Reg CF”) under the Securities Act of 1933, as amended.
The offering is being conducted through a registered intermediary funding portal. Interested investors may obtain information about the offering, including the offering circular and related materials, exclusively at:
No investment commitments will be accepted except through the funding portal listed above.
Important Disclosures
This communication is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities. Any such offer will be made only through the Company’s offering materials available on the funding portal in accordance with Regulation Crowdfunding.
Investing in securities offered under Regulation Crowdfunding involves risks, including the potential loss of your entire investment. Securities sold in a Regulation Crowdfunding offering are restricted and generally cannot be resold for at least one year.
Prospective investors should carefully review all offering materials, including risk factors, before making any investment decision.
About Zephyr Group
The Core Thesis: "Life to Years"
Zephyr Group, Inc. is an emerging biotechnology company dedicated to healthspan optimization. We are moving beyond the "reactive" healthcare model to develop evidence-based solutions at the intersection of therapeutic peptides, high-potency phytoceuticals, and advanced delivery systems. www.zephyrgroupinc.com
Media Contact
- Roy Serventi
CEO
drserventi@investzephyr.com
(480) 467-8347
